… In this phase 2, multicentre, non-randomised, open-label study, we enrolled previously
treated and untreated patients with stage IV metastatic BRAF V600E -positive NSCLC. Patients …

… In our open-label, multicentre, randomised phase 3 trial we enrolled eligible participants
attending hospitals in France, Italy, and Spain. Eligibility criteria included histological diagnosis …

Background Treatments for small-cell lung cancer (SCLC) after failure of platinum-based
chemotherapy are limited. We assessed safety and activity of nivolumab and nivolumab plus …

… We assessed the efficacy and safety of osimertinib in patients with EGFR Thr790Met-positive
non-small-cell lung cancer (NSCLC), who had progressed after previous therapy with an …

Background Outcomes are poor for patients with previously treated, advanced or metastatic
non-small-cell lung cancer (NSCLC). The anti-programmed death ligand 1 (PD-L1) antibody …

Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the
first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand …

… Multi-centre calibration of an adaptive thresholding method for PET-based delineation of
tumour volumes in radiotherapy planning of lung cancer. … radiotherapy planning of lung cancer. …

… In this multicentre, open-label, single-arm, phase 1–2 study, we examined the antitumour …
Open-Label, multicenter, phase ii study of ceritinib in patients with non-small-cell lung cancer …

Background ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK tyrosine
kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably develops, …

… lung cancer using the terms “ALK”, “ROS1”, “lung cancer”, … Association for the Study of
Lung Cancer meeting) using the … non-small-cell lung cancers (NSCLCs) are responsive to the …